Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY Putting It's Best Foot Forward

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Mar 14, 2023 9:42pm

123 Views

Post# 35338825

RE:RE:RE:RE:RE:ONCY Putting It's Best Foot Forward

Paid advertising to promote a real product that is available for sale is entirely different from boiler-room activity intended to solicit money from naive investors in a weak effort to inflate a weak company's penny stock.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023